Literature DB >> 11500425

Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom.

N K Fry1, S Neal, T G Harrison, E Miller, R Matthews, R C George.   

Abstract

The reemergence of pertussis has been reported in several countries despite high vaccination coverage. Studies in The Netherlands and Finland have investigated polymorphism in the genes coding for two important virulence factors of Bordetella pertussis, pertactin and pertussis toxin, and identified the emergence and subsequent dominance in circulating strains of pertactin and toxin variants not found in the whole-cell vaccine (WCV). The study described here investigated whether such variation had occurred in the United Kingdom, which presently has low levels of pertussis. Sequence analysis of the genes for pertactin (prnA) and the pertussis toxin S1 subunit (ptxA) among isolates of B. pertussis from 285 United Kingdom patients, from 1920 to 1999, revealed three prnA variants, prnA(1), prnA(2), and prnA(3), and two ptxA variants, ptxA(1) and ptxA(2), showing differences in nucleic acid sequence. The proportion of pertactin gene types not included in the United Kingdom WCV, i.e., prnA(2) and prnA(3), has increased in recent years and was found in 21 of 86 (24%) strains from the 1980s and 56 of 105 (53%) strains from the 1990s. To date, the presence of these nonvaccine prnA types has not been associated with a resurgence of pertussis in the United Kingdom. The distribution of prnA and ptxA types in The Netherlands, Finland, and the United Kingdom in the 1990s is distinct. The most striking difference in the United Kingdom isolates is that all 105 of the most recent circulating strains (from 1998 to 1999) are of a pertussis toxin type found in the United Kingdom WCV, i.e., ptxA(1).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11500425      PMCID: PMC98665          DOI: 10.1128/IAI.69.9.5520-5528.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

Review 1.  The science and fiction of pertussis vaccines.

Authors:  J D Cherry; P Olin
Journal:  Pediatrics       Date:  1999-12       Impact factor: 7.124

2.  Bordetella pertussis surveillance in England and Wales: 1995-7.

Authors:  P G Van Buynder; D Owen; J E Vurdien; N J Andrews; R C Matthews; E Miller
Journal:  Epidemiol Infect       Date:  1999-12       Impact factor: 2.451

3.  Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis.

Authors:  J Taranger; B Trollfors; T Lagergård; V Sundh; D A Bryla; R Schneerson; J B Robbins
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

4.  Epidemiological typing of Bordetella pertussis isolates: recommendations for a standard methodology.

Authors:  F R Mooi; H Hallander; C H Wirsing von König; B Hoet; N Guiso
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-03       Impact factor: 3.267

5.  Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland.

Authors:  F R Mooi; Q He; H van Oirschot; J Mertsola
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

6.  Pertussis in Quebec: ongoing epidemic since the late 1980s.

Authors:  G De Serres; N Boulianne; M Douville Fradet; B Duval
Journal:  Can Commun Dis Rep       Date:  1995-03-15

7.  Return of epidemic pertussis in the United States.

Authors:  J W Bass; R R Wittler
Journal:  Pediatr Infect Dis J       Date:  1994-05       Impact factor: 2.129

8.  Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution.

Authors:  F R Mooi; H van Oirschot; K Heuvelman; H G van der Heide; W Gaastra; R J Willems
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

9.  An aerosol challenge model of Bordetella pertussis infection as a potential bioassay for acellular pertussis vaccines.

Authors:  D K Xing; R G Das; L Williams; C Canthaboo; J Tremmil; M J Corbel
Journal:  Vaccine       Date:  1999-02-12       Impact factor: 3.641

10.  Molecular cloning and characterization of protective outer membrane protein P.69 from Bordetella pertussis.

Authors:  I G Charles; G Dougan; D Pickard; S Chatfield; M Smith; P Novotny; P Morrissey; N F Fairweather
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

View more
  34 in total

1.  Whooping cough--a continuing problem.

Authors:  N S Crowcroft; Joseph Britto
Journal:  BMJ       Date:  2002-06-29

2.  Multiple-locus variable-number tandem repeat analysis of Dutch Bordetella pertussis strains reveals rapid genetic changes with clonal expansion during the late 1990s.

Authors:  Leo M Schouls; Han G J van der Heide; Luc Vauterin; Paul Vauterin; Frits R Mooi
Journal:  J Bacteriol       Date:  2004-08       Impact factor: 3.490

3.  Simple Algorithm for Identification of Bordetella pertussis Pertactin Gene Variants.

Authors:  Gaëtan Muyldermans; Denis Piérard; Nathalie Hoebrekx; Reza Advani; Shirley Van Amersfoorth; Iris De Schutter; Oriane Soetens; Leo Eeckhout; Anne Malfroot; Sabine Lauwers
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

4.  Antigenic divergence suggested by correlation between antigenic variation and pulsed-field gel electrophoresis profiles of Bordetella pertussis isolates in Japan.

Authors:  Atsuko Kodama; Kazunari Kamachi; Yoshinobu Horiuchi; Toshifumi Konda; Yoshichika Arakawa
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

5.  Polymorphisms of the fimbria fim3 gene of Bordetella pertussis strains isolated in Canada.

Authors:  Raymond S W Tsang; Allan K H Lau; Michelle L Sill; Scott A Halperin; Paul Van Caeseele; Frances Jamieson; Irene E Martin
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

6.  Antigenic divergence of Bordetella pertussis isolates in Taiwan.

Authors:  Shu-Man Yao; Yu-Chi Lin; Chen-Ying Chou; Ying-Yan Chen; Miao-Ju Hsiao; Hour-Young Chen; Jer-Jea Yan; Hsun-Pi Su; Shu-Ying Li
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

7.  Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs.

Authors:  Hans O Hallander; Abdolreza Advani; Declan Donnelly; Lennart Gustafsson; Rose-Marie Carlsson
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

8.  Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains.

Authors:  Olga Borisova; Svetlana Yu Kombarova; Nelli S Zakharova; Marjolein van Gent; Vladimir A Aleshkin; Isabella Mazurova; Frits R Mooi
Journal:  Clin Vaccine Immunol       Date:  2007-01-03

9.  Changes in genetic diversity of the Bordetella pertussis population in the United Kingdom between 1920 and 2006 reflect vaccination coverage and emergence of a single dominant clonal type.

Authors:  David J Litt; Shona E Neal; Norman K Fry
Journal:  J Clin Microbiol       Date:  2009-01-21       Impact factor: 5.948

10.  Strain variation among Bordetella pertussis isolates circulating in Poland after 50 years of whole-cell pertussis vaccine use.

Authors:  Ewa Mosiej; Ewa Augustynowicz; Monika Zawadka; Waldemar Dabrowski; Anna Lutyńska
Journal:  J Clin Microbiol       Date:  2011-02-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.